Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a Children’s Oncology Group phase II study

PURPOSE: Combining anti-GD2 (disialoganglioside) monoclonal antibody with GM-CSF, IL2 and isotretinoin is now FDA-approved for high-risk neuroblastoma (NB) minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinical activity in NB and is more...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Shusterman, Suzanne, Naranjo, Arlene, Van Ryn, Collin, Hank, Jaquelyn A., Parisi, Marguerite T., Shulkin, Barry L., Servaes, Sabah, London, Wendy B., Shimada, Hiroyuki, Gan, Jacek, Gillies, Steven D., Maris, John M., Park, Julie R., Sondel, Paul M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945765/
https://ncbi.nlm.nih.gov/pubmed/31358541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0798
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller